Cost‐effectiveness study of <scp>FIB</scp>‐4 followed by transient elastography screening strategy for advanced hepatic fibrosis in a <scp>NAFLD</scp> at‐risk population
Cost‐effectiveness study of <scp>FIB</scp>‐4 followed by transient elastography screening strategy for advanced hepatic fibrosis in a <scp>NAFLD</scp> at‐risk population is a paper indexed in PICO Portal from OpenAlex.
How many citations does Cost‐effectiveness study of <scp>FIB</scp>‐4 followed by transient elastography screening strategy for advanced hepatic fibrosis in a <scp>NAFLD</scp> at‐risk population have?
Cost‐effectiveness study of <scp>FIB</scp>‐4 followed by transient elastography screening strategy for advanced hepatic fibrosis in a <scp>NAFLD</scp> at‐risk population has 19 citations in the OpenAlex counts PICO Portal stores.
When was Cost‐effectiveness study of <scp>FIB</scp>‐4 followed by transient elastography screening strategy for advanced hepatic fibrosis in a <scp>NAFLD</scp> at‐risk population published?
Cost‐effectiveness study of <scp>FIB</scp>‐4 followed by transient elastography screening strategy for advanced hepatic fibrosis in a <scp>NAFLD</scp> at‐risk population has 2024 year in the PICO Portal index.
What is the open-access status of Cost‐effectiveness study of <scp>FIB</scp>‐4 followed by transient elastography screening strategy for advanced hepatic fibrosis in a <scp>NAFLD</scp> at‐risk population?
Cost‐effectiveness study of <scp>FIB</scp>‐4 followed by transient elastography screening strategy for advanced hepatic fibrosis in a <scp>NAFLD</scp> at‐risk population has closed oa status in the PICO Portal index.
What is the DOI of Cost‐effectiveness study of <scp>FIB</scp>‐4 followed by transient elastography screening strategy for advanced hepatic fibrosis in a <scp>NAFLD</scp> at‐risk population?
The DOI for Cost‐effectiveness study of <scp>FIB</scp>‐4 followed by transient elastography screening strategy for advanced hepatic fibrosis in a <scp>NAFLD</scp> at‐risk population is on the source record.
What is the PMID of Cost‐effectiveness study of <scp>FIB</scp>‐4 followed by transient elastography screening strategy for advanced hepatic fibrosis in a <scp>NAFLD</scp> at‐risk population?
The PMID for Cost‐effectiveness study of <scp>FIB</scp>‐4 followed by transient elastography screening strategy for advanced hepatic fibrosis in a <scp>NAFLD</scp> at‐risk population is on the source record.
What is the OpenAlex record for Cost‐effectiveness study of <scp>FIB</scp>‐4 followed by transient elastography screening strategy for advanced hepatic fibrosis in a <scp>NAFLD</scp> at‐risk population?
The OpenAlex for Cost‐effectiveness study of <scp>FIB</scp>‐4 followed by transient elastography screening strategy for advanced hepatic fibrosis in a <scp>NAFLD</scp> at‐risk population is on the source record.